Related Experiment Video
Updated: Aug 29, 2026
Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis
Published on: February 13, 2026
Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of
M-H Wu1, H Yokozeki, S Takagawa
1Department of Dermatology and Immunodermatology, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan.
Abstract:
Systemic sclerosis (SSc) is a connective tissue disorder with an unknown etiology. There are currently no effective therapies for SSc. (In this study, working with a bleomycin(BLM)-induced scleroderma model mice, we performed two transfections of human hepatocyte growth factor (HGF) cDNA into the skeletal muscle and showed that this treatment not only helped to prevent the dermal sclerosis simultaneously injected BLM but also improved the symptoms of dermal sclerosis induced by BLM 4 weeks previously.) RT-PCR, ELISA and an immunohistochemical analysis revealed that both mRNA and protein of human HGF as well as murine HGF were enhanced in the skin, lung, muscle and the serum after two transfections of human HGF cDNA. These analyses also revealed that this treatment significantly reduced both the expression of the TGF-beta1 mRNA and the production of TGF-beta1 on macrophage-like cells that infiltrated the dermis and the fibroblastic cells in BLM-induced scleroderma. Furthermore, HGF-gene transfection both prevented and ameliorated the symptoms of not only dermal sclerosis but also of lung fibrosis induced by a subcutaneous BLM injection. These results indicated that gene therapy by the transfection of the human HGF cDNA may thus be a useful therapy for SSc and lung fibrosis involved with SSc.
Insights
Hepatocyte growth factor (HGF) gene therapy prevented and treated skin and lung fibrosis in a systemic sclerosis mouse model. This novel approach shows promise for treating systemic sclerosis (SSc) and related lung conditions.
Area of Science:
- Connective tissue disorders
- Fibrosis research
- Gene therapy applications
Background:
- Systemic sclerosis (SSc) is a debilitating connective tissue disorder with unknown causes and no effective treatments.
- Bleomycin (BLM)-induced mouse models are crucial for studying SSc pathogenesis and testing therapies.
Purpose of the Study:
- To investigate the therapeutic potential of human hepatocyte growth factor (HGF) gene therapy in a bleomycin (BLM)-induced systemic sclerosis mouse model.
- To evaluate HGF's effects on dermal sclerosis and lung fibrosis associated with SSc.
Main Methods:
- Two transfections of human HGF cDNA into skeletal muscle of BLM-induced scleroderma model mice.
- Analysis using RT-PCR, ELISA, and immunohistochemistry to measure HGF, TGF-beta1 levels, and cellular changes.
- Assessment of both preventative and therapeutic effects on dermal and lung fibrosis.
Main Results:
- HGF gene transfection significantly increased both human and murine HGF mRNA and protein levels in skin, lung, muscle, and serum.
- The treatment markedly reduced TGF-beta1 mRNA expression and production in infiltrated macrophages and fibroblasts.
- HGF gene therapy effectively prevented and ameliorated dermal sclerosis and lung fibrosis induced by BLM.
Conclusions:
- HGF gene therapy demonstrates significant potential as a therapeutic strategy for systemic sclerosis (SSc).
- This approach may also be effective in treating lung fibrosis associated with SSc.
- Further research into HGF gene therapy could lead to novel treatments for fibrotic diseases.
